Papillary thyroid cancer (PTC) accounts for 95% of differentiated thyroid cancers and is increasing in incidence at an estimated rate of 4% to 5% per year, with 56 870 cases predicted to be diagnosed in 2017 in the United States.1,2 The majority of patients with PTC have characteristic cytological findings and can be diagnosed by preoperative fine needle aspiration biopsy. Historically, treatment has included thyroidectomy with or without radioactive iodine ablation and is associated with an overall 20-year survival rate of greater than 90%.3 Greater understanding of the biology and natural history of these tumors suggests that not all patients with PTC require the same treatment intensity.
Yip L, Carty SE. Expanding the Options for Patient-Guided Decision Making in Papillary Thyroid Cancer. JAMA. 2018;319(1):76–77. doi:10.1001/jama.2017.18608
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: